Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients.
J Intern Med
; 291(2): 232-240, 2022 02.
Article
in English
| MEDLINE | ID: covidwho-1455598
ABSTRACT
BACKGROUND:
Anti-SARS-CoV-2 S antibodies prevent viral replication. Critically ill COVID-19 patients show viral material in plasma, associated with a dysregulated host response. If these antibodies influence survival and viral dissemination in ICU-COVID patients is unknown. PATIENTS/METHODS:
We studied the impact of anti-SARS-CoV-2 S antibodies levels on survival, viral RNA-load in plasma, and N-antigenaemia in 92 COVID-19 patients over ICU admission.RESULTS:
Frequency of N-antigenaemia was >2.5-fold higher in absence of antibodies. Antibodies correlated inversely with viral RNA-load in plasma, representing a protective factor against mortality (adjusted HR [CI 95%], p) (S IgM [AUC ≥ 60] 0.44 [0.22; 0.88], 0.020); (S IgG [AUC ≥ 237] 0.31 [0.16; 0.61], <0.001). Viral RNA-load in plasma and N-antigenaemia predicted increased mortality (N1-viral load [≥2.156 copies/ml] 2.25 [1.16; 4.36], 0.016); (N-antigenaemia 2.45 [1.27; 4.69], 0.007).CONCLUSIONS:
Low anti-SARS-CoV-2 S antibody levels predict mortality in critical COVID-19. Our findings support that these antibodies contribute to prevent systemic dissemination of SARS-CoV-2.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Antibodies, Viral
/
Antigens, Viral
Type of study:
Etiology study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Intern Med
Journal subject:
Internal Medicine
Year:
2022
Document Type:
Article
Affiliation country:
Joim.13386
Similar
MEDLINE
...
LILACS
LIS